44 related articles for article (PubMed ID: 38701062)
1. Early therapy evaluation of intra-arterial trastuzumab injection in a human breast cancer xenograft model using multiparametric MR imaging.
Kim BK; Kim B; You SH; Jang MS; Im GH; Kim KH
PLoS One; 2024; 19(5):e0300171. PubMed ID: 38701062
[TBL] [Abstract][Full Text] [Related]
2. Multiparametric MR imaging of tumor response to intraarterial chemotherapy in orthotopic xenograft models of human metastatic brain tumor.
Kim B; Kim K; Im KH; Kim JH; Lee JH; Jeon P; Byun H
J Neurooncol; 2016 Apr; 127(2):243-51. PubMed ID: 26746691
[TBL] [Abstract][Full Text] [Related]
3. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with
Al-Saden N; Lam K; Chan C; Reilly RM
Mol Pharm; 2018 Aug; 15(8):3383-3393. PubMed ID: 29957952
[TBL] [Abstract][Full Text] [Related]
4. Trastuzumab improves tumor perfusion and vascular delivery of cytotoxic therapy in a murine model of HER2+ breast cancer: preliminary results.
Sorace AG; Quarles CC; Whisenant JG; Hanker AB; McIntyre JO; Sanchez VM; Yankeelov TE
Breast Cancer Res Treat; 2016 Jan; 155(2):273-84. PubMed ID: 26791520
[TBL] [Abstract][Full Text] [Related]
5. miR‑135b‑5p enhances the sensitivity of HER‑2 positive breast cancer to trastuzumab via binding to cyclin D2.
Li Z; Qin Y; Chen P; Luo Q; Shi H; Jiang X
Int J Mol Med; 2020 Oct; 46(4):1514-1524. PubMed ID: 32700749
[TBL] [Abstract][Full Text] [Related]
6. Strategies for Improved Intra-arterial Treatments Targeting Brain Tumors: a Systematic Review.
Huang R; Boltze J; Li S
Front Oncol; 2020; 10():1443. PubMed ID: 32983974
[TBL] [Abstract][Full Text] [Related]
7. DCE-MRI-Derived Volume Transfer Constant (K
Ye ZM; Dai SJ; Yan FQ; Wang L; Fang J; Fu ZF; Wang YZ
Technol Cancer Res Treat; 2018 Jan; 17():1533034618765254. PubMed ID: 29642773
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab uptake and its relation to efficacy in an animal model of HER2-positive breast cancer brain metastasis.
Lewis Phillips GD; Nishimura MC; Lacap JA; Kharbanda S; Mai E; Tien J; Malesky K; Williams SP; Marik J; Phillips HS
Breast Cancer Res Treat; 2017 Aug; 164(3):581-591. PubMed ID: 28493046
[TBL] [Abstract][Full Text] [Related]
9. Early perfusion MRI predicts survival outcome in patients with recurrent glioblastoma treated with bevacizumab and carboplatin.
Bennett IE; Field KM; Hovens CM; Moffat BA; Rosenthal MA; Drummond K; Kaye AH; Morokoff AP
J Neurooncol; 2017 Jan; 131(2):321-329. PubMed ID: 27896520
[TBL] [Abstract][Full Text] [Related]
10. Correlation of tumor characteristics derived from DCE-MRI and DW-MRI with histology in murine models of breast cancer.
Barnes SL; Sorace AG; Loveless ME; Whisenant JG; Yankeelov TE
NMR Biomed; 2015 Oct; 28(10):1345-56. PubMed ID: 26332194
[TBL] [Abstract][Full Text] [Related]
11. Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.
Schmainda KM; Zhang Z; Prah M; Snyder BS; Gilbert MR; Sorensen AG; Barboriak DP; Boxerman JL
Neuro Oncol; 2015 Aug; 17(8):1148-56. PubMed ID: 25646027
[TBL] [Abstract][Full Text] [Related]
12. Magnetic resonance imaging-based tumour perfusion parameters are biomarkers predicting response after radiation to brain metastases.
Jakubovic R; Sahgal A; Soliman H; Milwid R; Zhang L; Eilaghi A; Aviv RI
Clin Oncol (R Coll Radiol); 2014 Nov; 26(11):704-12. PubMed ID: 25023291
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
